At BD, where he served as Vice President of Preclinical Development and Toxicology, David built and led GLP-compliant laboratories, directed cross-functional safety programs, and authored more than 300 health-risk assessments—supporting a global product portfolio exceeding $15 billion in annual revenue. His thought leadership has shaped industry best practices and informed FDA and ISO working groups across biocompatibility and toxicologic strategy.

At Endpoint, David brings a uniquely integrative approach to preclinical program design. He acts as a program architect, building phased, hypothesis-driven roadmaps that align toxicology, analytical data, and clinical objectives. He supports clients at every stage of development—from experimental design and study data interpretation to regulatory submission and post-market strategy. Whether serving as a fractional advisor or delivering targeted toxicology consulting, his expertise helps teams define gaps, manage risk, and present credible, decision-ready findings.

David’s knowledge of GLP and ISO-compliant laboratory systems is also an asset to clients setting up and optimizing in-house testing or requiring support in study placements. His experience spans general surgery, interventional and model development studies, in-vitro and in-vivo toxicology programs, proof of concept, and cross-disciplinary evidence synthesis—drawing from imaging, pathology, PK, and clinical chemistry data to support comprehensive safety narratives.